Literature DB >> 18367976

Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations.

Jeannina Smith1, David Andes.   

Abstract

Therapeutic drug monitoring of any pharmacologic agent should be considered when there is both significant pharmacokinetic variability and strong, clinically relevant, exposure-effect relationships. Many antifungal drugs exhibit marked variability in drug concentration as a result of inconsistent absorption, metabolism, elimination, or interaction with concomitant medications. For each of the available antifungal drugs, both preclinical and clinical trials have exhibited a relationship between serum concentrations and treatment efficacy. For a smaller subset of compounds, a similar relationship has been identified for the toxicity. The kinetic variability among patients falls outside the therapeutic window for a group of four antifungal compounds. This review summarizes the current literature on therapeutic drug monitoring for these antifungal agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18367976     DOI: 10.1097/FTD.0b013e318167d0e0

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  37 in total

1.  Intracellular concentrations of posaconazole in different compartments of peripheral blood.

Authors:  Fedja Farowski; Oliver A Cornely; Jörg J Vehreschild; Pia Hartmann; Tim Bauer; Angela Steinbach; Maria J G T Rüping; Carsten Müller
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Therapeutic drug monitoring of antimicrobials.

Authors:  Jason A Roberts; Ross Norris; David L Paterson; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

Review 3.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

4.  In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations.

Authors:  Pilar Escribano; Sandra Recio; Teresa Peláez; Milagros González-Rivera; Emilio Bouza; Jesús Guinea
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

5.  Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.

Authors:  Maud Berge; Romain Guillemain; David A Trégouet; Catherine Amrein; Veronique Boussaud; Patrick Chevalier; Agnes Lillo-Lelouet; Christine Le Beller; Pierre Laurent-Puig; Philippe H Beaune; Eliane M Billaud; Marie-Anne Loriot
Journal:  Eur J Clin Pharmacol       Date:  2010-10-31       Impact factor: 2.953

6.  Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography.

Authors:  Kathrin Kahle; Peter Langmann; Diana Schirmer; Ulrike Lenker; Daniela Keller; Annegret Helle; Hartwig Klinker; Werner J Heinz
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

7.  International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations.

Authors:  Roger J M Brüggemann; Daan J Touw; Rob E Aarnoutse; Paul E Verweij; David M Burger
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

8.  Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations.

Authors:  Piergiorgio Cojutti; Anna Candoni; Erica Simeone; Loretta Franceschi; Renato Fanin; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

9.  Therapeutic drug monitoring in voriconazole-associated hyponatremia.

Authors:  Ren-Ai Xu; Shuang-Li Zheng; Li-Li Xiao; Xue-Ding Cai; Xi-Xi Lai; Guan-Yang Lin; Lu-Feng Hu; Chun-Hong Zhang; Zhi-Sheng Xu; Xiu-Hua Zhang
Journal:  Med Mycol Case Rep       Date:  2013-06-19

10.  Voriconazole pharmacokinetics and pharmacodynamics in children.

Authors:  Michael Neely; Teresa Rushing; Andrea Kovacs; Roger Jelliffe; Jill Hoffman
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.